Trials / Completed
CompletedNCT04202159
A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures
PERPRISE: A Prospective Non-interventional Study Evaluating the Effectiveness of Perampanel (Fycompa®) as Only Add-on Treatment in Patients With Primary or Secondarily Generalized Tonic-clonic Seizures
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 187 (actual)
- Sponsor
- Eisai GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to investigate the effectiveness reflected by the retention rate of perampanel as the only add-on treatment in adult participants with primary generalized tonic-clonic (PGTC) or secondarily generalized tonic-clonic (SGTC) seizures based on focal or idiopathic generalized epilepsy in a non-interventional (observational) setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Perampanel | Perampanel tablets. |
| DRUG | Perampanel | Perampanel oral suspension. |
Timeline
- Start date
- 2020-01-21
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
- First posted
- 2019-12-17
- Last updated
- 2023-08-03
Locations
34 sites across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04202159. Inclusion in this directory is not an endorsement.